S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:ADVMAdverum Biotechnologies Stock Price, Forecast & News

$18.20
+0.56 (+3.17 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.61
Now: $18.20
$18.37
50-Day Range
$16.65
MA: $20.03
$25.64
52-Week Range
$4.96
Now: $18.20
$26.98
Volume463,906 shs
Average Volume1.38 million shs
Market Capitalization$1.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.06
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Read More
Adverum Biotechnologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-656-9323

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$250,000.00
Book Value$2.71 per share

Profitability

Net Income$-64,490,000.00

Miscellaneous

Employees82
Market Cap$1.46 billion
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$18.20
+0.56 (+3.17 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

How has Adverum Biotechnologies' stock been impacted by COVID-19 (Coronavirus)?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADVM stock has increased by 96.5% and is now trading at $18.20.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Adverum Biotechnologies?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 1 sell rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adverum Biotechnologies
.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Adverum Biotechnologies
.

How can I listen to Adverum Biotechnologies' earnings call?

Adverum Biotechnologies will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) released its earnings results on Thursday, May, 28th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04.
View Adverum Biotechnologies' earnings history
.

What price target have analysts set for ADVM?

9 Wall Street analysts have issued 1-year price targets for Adverum Biotechnologies' stock. Their forecasts range from $17.00 to $36.00. On average, they anticipate Adverum Biotechnologies' share price to reach $23.63 in the next twelve months. This suggests a possible upside of 29.8% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
.

Has Adverum Biotechnologies been receiving favorable news coverage?

Media stories about ADVM stock have trended somewhat negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Adverum Biotechnologies earned a news impact score of -1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future.
View the latest news about Adverum Biotechnologies
.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Endologix (ELGX), Immunomedics (IMMU), Amarin (AMRN), Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG) and Crispr Therapeutics (CRSP).

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 52)
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 60)
  • Dr. Amber Salzman, Consultant (Age 57)
  • Ms. Leone D. Patterson, CEO & Director (Age 56)
  • Mr. Thomas Leung, Chief Financial Officer

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include Versant Venture Management LLC (8.72%), UBS Group AG (2.07%), Rhenman & Partners Asset Management AB (0.62%), Assenagon Asset Management S.A. (0.40%), Candriam Luxembourg S.C.A. (0.28%) and Swiss National Bank (0.17%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Leone D Patterson and Mehdi Gasmi.
View institutional ownership trends for Adverum Biotechnologies
.

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Versant Venture Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, Parallel Advisors LLC, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Adverum Biotechnologies company stock in the last year include Leone D Patterson, and Mehdi Gasmi.
View insider buying and selling activity for Adverum Biotechnologies
.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Mackay Shields LLC, Candriam Luxembourg S.C.A., Swiss National Bank, Dupont Capital Management Corp, Russell Investments Group Ltd., ProShare Advisors LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Adverum Biotechnologies
.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $18.20.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $1.46 billion and generates $250,000.00 in revenue each year. The biotechnology company earns $-64,490,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is www.adverum.com.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.